Novartis: 1996 – 2013 Dr Daniel Vasella was the first CEO of the newly merged company. Vasella was hired by Sandoz back in 1988 and remained there until 1992 when he was promoted to CEO of its ...

The acquisition aligns with Novartis’ growth strategy and therapeutic area focus. Credit: © 2025 Novartis AG. Novartis has agreed to acquire Boston-based clinical ...

"Novartis signs agreement to acquire Anthos for $925m upfront" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been ...

Joint research activities will be carried out at Novartis’ sites in Basel, Switzerland, and Dublin, Ireland, as well as at the Microsoft Research Lab in Cambridge, UK.

subject to customary closing conditions Basel, February 11, 2025 – Novartis today announced that it has entered into an agreement to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, ...

Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the activated form ...

Novartis is expanding its prospects in cardiometabolic disease by striking a deal to acquire Anthos Therapeutics, a company in pivotal testing with a blood clot-preventing drug that could offer ...

Novartis To Beef Up Heart Disease Offering With $3 Billion Blackstone-Backed Anthos Therapeutics Deal Novartis is acquiring Anthos Therapeutics for up to $3.08 billion, adding abelacimab, a late ...

Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.